To Top
08:32 Δευτέρα
25 Μαρτίου 2019
Επόμενο
Προηγούμενο
MEPs throw weight behind medical cannabis 
  14 Φεβρουαρίου 2019, 11:46 πμ  

The European Parliament has approved a resolution calling on the European Commission and member states to address research gaps on medical cannabis and seize the potential of cannabis-based medicines.

The resolution calls for a clear distinction between medical cannabis and other uses of cannabis. And it urges the Commission and member states to address regulatory, financial and cultural barriers which burden scientific research and invites them to properly fund research.

The EU, too, should embark on more research and stimulate innovation with regard to medicinal cannabis projects.

Let doctors prescribe cannabis-based medicines

MEPs call on member states to allow doctors to use their professional judgement in prescribing cannabis-based medicines. When effective, these medicines are to be covered by health insurance schemes in the same way as other types of medicine, they say.

The regulation of cannabis-based medicines would translate into additional revenue for public authorities, would limit the black market and ensure quality and accurate labelling. It would also limit minors’ access to this substance, they say.

Background

MEPs say that there is evidence that cannabis or cannabinoids may be effective in increasing appetite and decreasing weight loss associated with HIV/AIDS.

Medical cannabis may also help to alleviate the symptoms of mental disorders such as psychosis or Tourette syndrome, and to alleviate the symptoms of epilepsy, as well as Alzheimer’s, arthritis, asthma, cancer, Crohn’s disease and glaucoma. They also help to reduce the risk of obesity and diabetes and ease menstrual pain.

Whilst the WHO has officially recommended that the cannabis compound cannabidiol (CBD) should not be classified as a controlled substance, legislation in member states differs widely on the subject of cannabis for medicinal purposes.

  Edited by Bouli Hadjioannou